Complete financial analysis of hVIVO plc (OPORF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of hVIVO plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Oranco, Inc. (ORNC) Income Statement Analysis – Financial Results
- Rennova Health, Inc. (RNVA) Income Statement Analysis – Financial Results
- Yanbu Cement Company (3060.SR) Income Statement Analysis – Financial Results
- Equital Ltd. (EQTL.TA) Income Statement Analysis – Financial Results
- Impacx.Io Ltd (IMPC.TA) Income Statement Analysis – Financial Results
hVIVO plc (OPORF)
About hVIVO plc
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.04M | 48.48M | 36.86M | 20.60M | 3.28M | 12.55M | 15.45M | 15.27M | 8.47M | 3.81M | 1.70M | 2.19M | 2.87M |
| Cost of Revenue | 45.63M | 44.47M | 963.00K | 727.00K | 8.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.41M | 4.00M | 35.90M | 19.88M | -4.78M | 12.55M | 15.45M | 15.27M | 8.47M | 3.81M | 1.70M | 2.19M | 2.87M |
| Gross Profit Ratio | 18.58% | 8.26% | 97.39% | 96.47% | -145.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 82.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.17M | 23.54M | 17.86M | 10.96M | 1.78M | 15.02M | 15.77M | 16.03M | 8.81M | 5.33M | 3.21M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 181.12K | 244.30K | 262.77K | 288.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.17M | 23.54M | 17.86M | 10.96M | 1.96M | 15.02M | 15.77M | 16.03M | 8.81M | 5.33M | 3.21M | 0.00 | 0.00 |
| Other Expenses | 21.77M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 45.94M | 42.34M | 35.61M | 28.43M | 7.57M | 14.68M | 15.41M | 15.74M | 8.68M | 5.20M | 3.21M | 3.11M | 3.59M |
| Cost & Expenses | 45.94M | 42.34M | 36.57M | 29.16M | 7.57M | 14.68M | 15.41M | 15.74M | 8.68M | 5.20M | 3.21M | 3.11M | 3.59M |
| Interest Income | 1.18M | 137.00K | 12.00K | 0.00 | 0.00 | 9.01K | 0.00 | 10.23K | 1.48K | 7.03K | 10.05K | 2.46K | 4.17K |
| Interest Expense | 155.00K | 133.00K | 227.00K | 374.00K | 340.88K | 5.41K | 0.00 | 0.00 | 32.47K | 55.47K | 34.33K | 23.73K | 12.52K |
| Depreciation & Amortization | 2.72M | 2.93M | 2.57M | 2.05M | 610.85K | 842.89K | 790.98K | 700.68K | 342.42K | 146.10K | 26.80K | 35.19K | 25.88K |
| EBITDA | 14.02M | 9.77M | 3.07M | -8.55M | -4.83M | -3.67M | -806.07K | -77.57K | 520.27K | -1.23M | -1.47M | -882.21K | 1.07M |
| EBITDA Ratio | 25.01% | 20.16% | 7.60% | -32.09% | -115.27% | 2.05% | 0.11% | -0.51% | 1.58% | -32.17% | -86.00% | -40.22% | -24.02% |
| Operating Income | 10.10M | 6.02M | 590.00K | -10.44M | -4.99M | -2.13M | 46.16K | -478.20K | -210.32K | -1.38M | -1.50M | -919.86K | 1.04M |
| Operating Income Ratio | 18.03% | 12.42% | 1.60% | -50.68% | -151.85% | -17.00% | 0.30% | -3.13% | -2.48% | -36.19% | -88.16% | -41.94% | 36.26% |
| Total Other Income/Expenses | 1.05M | -6.39M | -313.00K | -721.00K | -676.00K | -2.38M | -1.52M | -300.05K | -28.78K | -48.44K | -24.28K | -21.28K | -8.35K |
| Income Before Tax | 11.15M | -365.00K | 277.00K | -11.16M | -5.65M | -4.52M | -1.48M | -778.25K | -241.32K | -1.43M | -1.53M | -941.14K | 1.03M |
| Income Before Tax Ratio | 19.89% | -0.75% | 0.75% | -54.18% | -172.19% | -35.99% | -9.57% | -5.10% | -2.85% | -37.46% | -89.58% | -42.91% | 35.97% |
| Income Tax Expense | -4.97M | 411.00K | 351.00K | -372.00K | -64.93K | -211.85K | -112.74K | -144.06K | -92.25K | -15.63K | -19.26K | 18.00K | 21.70K |
| Net Income | 16.12M | -776.00K | -74.00K | -10.79M | -5.59M | -4.30M | -1.37M | 453.48K | 11.07K | -1.20M | -1.51M | -959.14K | 1.01M |
| Net Income Ratio | 28.75% | -1.60% | -0.20% | -52.38% | -170.21% | -34.30% | -8.84% | 2.97% | 0.13% | -31.39% | -88.45% | -43.73% | 35.21% |
| EPS | 0.02 | 0.00 | 0.00 | -0.02 | -0.03 | -0.06 | -0.02 | 0.01 | 0.00 | -0.04 | -0.08 | -0.09 | 0.05 |
| EPS Diluted | 0.02 | 0.00 | 0.00 | -0.02 | -0.03 | -0.06 | -0.02 | 0.01 | 0.00 | -0.04 | -0.08 | -0.09 | 0.05 |
| Weighted Avg Shares Out | 685.74M | 670.94M | 670.19M | 599.92M | 165.08M | 72.26M | 60.28M | 60.26M | 41.26M | 26.96M | 20.10M | 10.12M | 20.10M |
| Weighted Avg Shares Out (Dil) | 685.85M | 670.94M | 670.19M | 599.92M | 165.08M | 72.26M | 65.44M | 64.11M | 41.26M | 26.96M | 20.10M | 10.12M | 20.10M |
hVIVO announces new facility and major field study contract - ICYMI
hVIVO deal hailed by brokers; one thinks thinks the stock is worth 60p
hVIVO lands its largest field study to date as it bags phase II flu trial
hVIVO deal receives broker seal of approval
hVIVO lands £2.5m characterisation study contract for Covid variant
hVIVO primed for success, says US investment
hVIVO primed for success, says US investment
hVivo shares remain inexpensive, say analysts
hVivo shares remain inexpensive, say analysts
hVIVO launches annual dividend policy, sets new medium-term growth target
Source: https://incomestatements.info
Category: Stock Reports